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Preventive treatment of migraine
Stephen D. Silberstein
Jefferson Headache Center, 111 South 11th Street, Suite 8130, Philadelphia, PA 19107, USA
Email: stephen.silberstein@jefferson.edu

Abstract
Migraine is a common episodic pain disorder, the treatment of which can be acute to stop an
attack or preventive to reduce the frequency, duration or severity of attacks. Preventive treatment
is used when attacks are frequent or disabling. Many different medication groups are used for
preventive treatment, including β-blockers, antidepressants and antiepileptic drugs. Their
mechanisms of action include raising the threshold to migraine activation, enhancing
antinociception, inhibiting cortical spreading depression, inhibiting peripheral and central
sensitization, blocking neurogenic inflammation and modulating sympathetic, parasympathetic or
5-HT tone. In this article, I review evidence of the effectiveness of migraine preventive drugs. I
also discuss the setting of treatment priorities.

Introduction
Migraine is a common episodic headache disorder that is characterized by attacks comprising
various combinations of headache and neurological, gastrointestinal and autonomic symptoms. It
has a one-year prevalence of ~18% in women, 6% in men and 4% in children [1]. The
International Headache Society (http://www.i-h-s.org/ ) subclassifies migraine into migraine
without aura (1.1) and migraine with aura (1.2), the aura being the complex of focal neurological
symptoms that most often precedes or accompanies an attack [2]. The pharmacological treatment
of migraine can be acute (abortive) or preventive, and patients with frequent severe headaches
often require both approaches. Preventive migraine treatment also includes nonpharmacological
therapy, which is not discussed in this review. Preventive treatment is used to reduce the
frequency, duration or severity of attacks. Additional benefits include improvement of
responsiveness to acute attack treatment, improvement of function and reduction in disability.
Preventive treatment might preclude the progression of episodic migraine to chronic migraine
and result in reductions in the cost of health care [3]. In this article, I present background
information about migraine physiology, followed by a discussion of the available preventive
medications. This is divided into older generic drugs, newer, recently studied medications and
other drugs for which there is limited evidence of efficacy or that are perceived as natural
products.
Guidelines for the preventive treatment of migraine have been developed in the USA [4].
Indications include:
i. attacks that significantly interfere with a patient’s daily routine, despite appropriate acute
treatment;
ii. failure of, contraindication to or troublesome adverse events (AEs) from acute
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iii.
iv.
v.
vi.

medications;
acute medication overuse;
very frequent headaches (more than two per week);
patient preference;
special circumstances such as hemiplegic migraine or attacks with a risk of permanent
neurological injury.

Prevention is not being used to the extent that it should be; only 5% of all migraineurs currently
use preventive therapy to control their attacks [5].
Many medication groups are used for preventive migraine treatment (Table 1). The choice of
preventive medication is empiric; it is influenced by efficacy, AEs and the patient’s coexistent
and comorbid conditions [1]. The chosen preventive agent should be started at a low dose and
increased slowly until therapeutic effects develop or the ceiling dose is reached. A full
therapeutic trial can take two to six months.
Table 1. Preventive medications
Drug
ACE inhibitors and angiotensin receptor antagonists

Anticonvulsants
a
a
Topiramate , valproate , gabapentin, lamotrigine

Potential mechanism
Enkephalinase inhibition?
Enhance antinociception

Inhibit CSD, block NI, inhibit CS
Enhance antinociception

Antidepressants
b
TCAs, SNRIs, SSRIs

Inhibit CSD, enhance antinociception

β-Adrenoceptor blockers
a
a
Propranolol , timolol , nadolol, atenolol

Inhibit CSD, decrease sympathetic activity

Calcium channel antagonists
Flunarizine
Verapamil

Inhibits CSD, blocks dopamine receptor, inhibits NI
Inhibits CSD

Neurotoxins
b
Botulinum toxin
5-HT antagonists
Methysergide, methergine

Inhibit CS
b

Others
NSAIDS
b
Riboflavin, CoQ10, magnesium
b

Feverfew , butterroot
a

Inhibit CSD, inhibit NI

Block prostaglandin synthesis, inhibit CS
Normalize energy metabolism
Inhibit CS?

FDA approved.
Clinical trials inconclusive.

b
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Mechanism of action of preventive medications
The migraine aura is probably due to spreading depression (SD), a wave of electrical activity
(excitation followed by depression) that moves across the cerebral cortex at a rate of 2–3
mm/min. It is characterized by shifts in cortical steady-state potential, transient increases in K+,
nitric oxide and glutamate, and transient increases followed by sustained decreases in cerebral
blood flow [6,7] (Figure 1).

Figure 1. Migraine mechanisms. The migraine aura is due to CSD in a more sensitive CNS. The headache is due to
activation of trigeminal dural and perivascular afferents, resulting in neurogenic-mediated inflammation and plasma
protein extravasation. Headache is maintained by the sensitization of TNC neurons. SD can lead to the activation of
trigeminal neurons and results in the release of nitric oxide, glutamate and protons that can activate trigeminal
afferent nerves. Headache in the absence of aura might be generated by SD in the cerebellum or silent areas of the
cortex. In addition, parasympathetic nerves that are under brainstem control might activate trigeminal neurons. The
TNC is subject to both inhibitory and facilitatory descending modulation. Preventive drugs can inhibit CSD by
reducing central excitability, perhaps in part by blocking gap junctions. Preventive drugs can also enhance
descending inhibitory modulation and inhibit neurogenic inflammation or central pain transmission. In addition, they
might work on earlier, still unknown, parts of the migraine cascade.

Headache probably results from the activation of meningeal and blood vessel nociceptors,
combined with a change in central pain modulation. Headache and its associated neurovascular
changes are subserved by the trigeminal system. Trigeminal sensory neurons contain substance P
(SP), calcitonin-gene-related peptide and neurokinin A. In animal models, stimulation results in
the release of SP and calcitonin-gene-related peptide from sensory C-fiber terminals, and
neurogenic inflammation (NI) [7]. However, the role of SP in the pathophysiology of human
migraine is unclear [8].
In animal experiments, neuropeptides interact with the blood vessel wall, producing dilatation,
plasma protein extravasation and platelet activation [9]. Neurogenic inflammation sensitizes
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nerve fibers (peripheral sensitization), which then respond to previously innocuous stimuli such
as blood vessel pulsations, causing, in part, the pain of migraine. Central sensitization of
trigeminal nucleus caudalis (TNC) neurons can also occur and might have a key role in
maintaining the headache [10]. Brainstem activation also occurs in migraine without aura, in part
because of increased endogenous antinociceptive system activity. The migraine aura can trigger
headache; SD activates trigeminovascular afferents. What initiates the activation of
trigeminovascular afferents in the absence of a clinical aura? Potential mechanisms include SD in
silent areas of the cerebral cortex or cerebellum. In addition, trigeminal afferents might be
activated by events initiated in the brainstem. Stress can also activate meningeal plasma cells via
a parasympathetic mechanism, leading to nociceptor activation [11].
Most migraine preventive drugs were designed to treat other disorders. 5-HT antagonists were
developed based on the concept that migraine is due to excess 5-HT. Antidepressants
downregulate 5-HT2 and b-adrenoceptors. Anticonvulsant medications decrease glutamate levels
and enhance GABA. The potential mechanisms of migraine preventive medications include:
i. raising the threshold to migraine activation by stabilizing a more reactive nervous system;
ii. enhancing antinociception;
iii. inhibiting SD;
iv. inhibiting peripheral and/or central sensitization;
v.
blocking neurogenic inflammation;
vi. modulating sympathetic, parasympathetic or 5-HT tone.
Oshinski and Luo found that descending control from the upper brainstem, through 5-HTmediated and norepinephrine-mediated systems, modulates the TNC and prevents central
sensitization [12]. Ayata et al. have recently shown that preventive medications given
chronically, but not acutely, block SD [13].
New targets are being evaluated. Gap junctions are intercellular channels that enable the
diffusion of small molecules (up to 1 kDa). Vertebrate gap junction channels comprise 12 protein
subunits called connexins. Gap junctions have a central role in mechanisms underlying the
2+
initiation and propagation of SD. Gap junction inhibitors abolish both astrocytic Ca waves in
culture and SD [14].
The gap junction inhibitor tonabersat {(—)-cis-6-acetyl-4S-3-chloro-4-fluoro-benzoylamino-3,4dihydro-2,2-dimethyl-2H-benzo[p]pyran-3S-ol} has entered clinical trials for migraine.
Tonabersat inhibits cortical spreading depression (CSD), CSD-induced nitrous oxide release and
cerebral vasodilatation. It does not constrict isolated human blood vessels but it does inhibit
trigeminally induced craniovascular effects [15].

Older migraine preventive agents
β-Blockers
The mechanism of action of β-blockers is not clear but it could occur by the inhibition of β1mediated mechanisms [16]. β-Blockers, the most widely used class of prophylactic migraine
drug, are ~50% effective at producing a >50% reduction in attack frequency and include
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propranolol, nadolol, atenolol, metoprolol and timolol [17]. The relative efficacy of β-blockers
has not been established; choice is based on β-selectivity, convenience, AEs and patient
reactions. β-Blockers with intrinsic sympathomimetic activity (e.g., acebutolol, alprenolol,
oxprenolol and pindolol) are not effective for migraine prevention. β -Blockers can produce
behavioral AEs such as drowsiness, fatigue, lethargy, sleep disorders, nightmares, depression,
memory disturbance and hallucinations, and should be avoided when patients are depressed.
Decreased exercise tolerance limits their use by athletes. Less common AEs include impotence,
orthostatic hypotension and bradycardia [18].
Antidepressants
There are several different classes of antidepressant that have different mechanisms of action. In
animal pain models, antidepressants potentiate the effects of co-administered opioids [16].
Amitriptyline (a tricyclic antidepressant) is the only antidepressant with consistent support for
efficacy [17]. AEs include increased appetite, weight gain, dry mouth and sedation; cardiac
toxicity and orthostatic hypotension occasionally occur. Selective 5-HT reuptake inhibitors
(SSRIs) are probably not effective at preventing migraine, whereas the results of open and
smaller studies indicate that selective norepinephrinereuptake inhibitors (SNRIs) are effective
[19]. The mechanism by which antidepressants prevent headache is unclear but it does not result
from treating masked depression.
2+

Ca channel antagonists
2+

Ca channel antagonists were introduced for the treatment of migraine on the assumption that
they prevent hypoxia of cerebral neurons, contraction of vascular smooth muscle and inhibition
2+

of the Ca -dependent enzymes involved in prostaglandin formation. Perhaps it is their ability to
block 5-HT release, interfere with neurovascular inflammation or interfere with the initiation and
propagation of SD that is crucial [16]. The discovery that an abnormality in an a1A subunit (P/Q
channel) can produce familial hemiplegic migraine has led to a search for more-fundamental
associations [20].
Of the drugs in this class [17], flunarizine is effective at preventing migraine, whereas
nimodipine and nifedipine are probably not. The efficacy of verapamil, despite its wide use in the
USA (because flunarizine is unavailable), is uncertain, and its most common AE is constipation.
The AEs of flunarizine include parkinsonism, depression and weight gain. These are typical of
dopamine antagonists and indicate an alternative mechanism of action.
Newer drugs
Anticonvulsants
Because of the proven effectiveness of anticonvulsants and because of the belief that migraine is
due to CNS hyperexcitability, headache experts increasingly recommend anticonvulsant
medication for migraine prevention. With the exception of topiramate, valproic acid and
zonisamide, anticonvulsants can interfere substantially with the efficacy of oral contraceptives
[21,22]. They are discussed in order of efficacy in terms of migraine prevention.
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Topiramate
Topiramate was originally synthesized as part of a research project to develop structural analogs
of fructose-1,6-diphosphate that could inhibit the enzyme fructose 1,6-bisphosphatase, thereby
blocking gluconeogenesis, but it has no hypoglycemic activity. Topiramate was originally
marketed for the treatment of epilepsy [23] but is now approved by the Food and Drug
Administration (FDA, http://www.fda.gov/ ) for migraine treatment. Topiramate is rapidly and
almost completely absorbed, not extensively metabolized [24] and it readily enters the CNS
[25,26]. It is not associated with significant reductions in estrogen exposure at doses <200
mg/day.
+

2+

Topiramate can influence the activity of some types of voltage-activated Na and Ca channels,
GABAA receptors and the AMPA/kainate subtype of glutamate receptor [27,25]. It also inhibits
some isozymes of carbonic anhydrase (CA) and exhibits selectivity for CA II and CA IV [28].
+
Topiramate blocks Na channels in a voltage-sensitive, use-dependent manner [29]. It reduces the
+

amplitude of tetrodotoxin-sensitive voltage-gated Na currents in rat cerebellar granule cells, as
+

measured by whole-cell current-clamp recordings [30]. Its effects on voltage-activated Na and
2+

Ca channels, GABAA receptors and AMPA/kainate receptors are regulated by protein
phosphorylation [31–34]. Subunits of each complex are phosphorylated by protein kinase (PK)A,
2+

PKC and possibly Ca /calmodulin-activated kinases. Topiramate might prevent PKA from
phosphorylating these moieties, which would shift a population of channels towards the
dephosphorylated state, thereby modulating channel and receptor activity [26].
Neuron activation within the trigeminocervical complex is likely to be the biological substrate
for pain in migraine and cluster headache. Topiramate reduces superior-sagittal-sinus-evoked
firing of neurons in the trigeminocervical complex in a dose-dependent fashion [35]. This
inhibition is a plausible mechanism of its action in migraine prevention. Topiramate was
effective in several open-label and pilot studies and in three large, multicenter, randomized,
double-blind, placebo-controlled clinical trials. In addition, its chronic use has been associated
with weight loss rather than weight gain.
Two large, pivotal, multicenter, randomized, double-blind, placebo-controlled clinical trials
assessed the efficacy and safety of topiramate (50, 100 and 200 mg/day) in migraine prevention
and found it to be effective at all doses [36,37]. A third trial compared two doses of topiramate
(100 mg/day and 200 mg/day) with placebo or propranolol (160 mg/day) [38]. A dose of 100
mg/day of topiramate was superior to placebo in terms of migraine prevention. The results of the
topiramate 100-mg/day and the propranolol groups were similar. The 100-mg/day dose of
topiramate has the best effectiveness: AE ratio.
The most common AEs of topiramate are paresthesia, fatigue, decreased appetite, nausea,
diarrhea, weight decrease, taste perversion, hypoesthesia and abdominal pain. Common CNS
AEs are somnolence, insomnia, memory difficulties, language problems, concentration
difficulties, mood problems and anxiety. Renal calculi can occur: their reported incidence is
~1.5%, representing a twofold to fourfold increase compared with the estimated occurrence in
the general population [39]. Acute myopia associated with secondary angle-closure glaucoma
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has been reported infrequently in patients receiving topiramate [40]. Oligohidrosis has also been
reported in association with an elevation in body temperature.
Weight loss seems to be greatest in patients who are heavier at the onset of treatment and is seen
most commonly in women [41]. The exact mechanism underlying weight loss is unclear. Rats
given topiramate showed decreased levels of body fat, in addition to acutely reduced food intake
and an increased metabolic rate. These animals also had decreased levels of total insulin, leptin
and corticosterone [42]. Topiramate inhibits fat deposition, and the activity of lipoprotein lipase
is reduced in adipose tissue in topiramate-treated rats [43].
Valproic acid
Valproic acid is a simple eight-carbon, two-chain fatty acid with anticonvulsant activity in a wide
range of experimental epilepsy models. The mechanism of action of valproate in migraine
prevention might be related to the facilitation of GABA-mediated neurotransmission [44–48].
Valproate enhances GABA activity within the brain by inhibiting its degradation, stimulating its
synthesis and release, and directly enhancing its postsynaptic effects. The valproate
concentration required to inhibit GABA transaminase is greater than that which occurs during
therapy. However, active metabolites (e.g. 2-en-valproic acid) accumulate in the brain, have an
anticonvulsant effect and cause GABA accumulation in vivo [45]. Other potential mechanisms of
action include direct effects on neuronal membranes (suppressing induced and spontaneous
epileptiform activity), inhibition of kindling and reduction of excitatory neurotransmission by
aspartate by blocking its release [47,48]. Valproate also attenuates NI by interacting with the
GABAA receptor, which might be on the parasympathetic nerve fibers that project from the
sphenopalatine ganglia; in so doing, it attenuates nociceptive neurotransmission [45]. Increased
central enhancement of GABAA activity might enhance central antinociception [49]. Valproate
also interacts with the central 5-HT system and reduces the firing rate of midbrain 5-HTcontaining neurons [49].
Consistent evidence supports the efficacy of divalproex sodium (approved by the FDA) [17],
sodium valproate [17] and the extended-release formulation [50]. The effective dose for migraine
of both divalproex sodium and sodium valproate is lower than that for epilepsy. The most
frequent AEs are nausea, alopecia, tremor, asthenia, dyspepsia, somnolence and weight gain
[51]. Hepatotoxicity and pancreatitis are the most serious AEs but irreversible hepatic
dysfunction is extremely rare in adults [52]. Divalproex carries a high risk of congenital
abnormality [46].
Gabapentin
Gabapentin is used to treat certain forms of epilepsy, neuropathic pain and migraine. It binds
with high affinity to two of the four known α2δ subunits (α2δ-1 and α2δ-2) of voltage-gated Ca2+
channels. This produces inhibition of high-voltage-activated Ca2+ currents, resulting in a
reduction of synaptic transmission. This could be how gabapentin reduces fast glutamatemediated and glycine-mediated synaptic transmission [53,54]. Gabapentin might be effective in
migraine but the trial results are not conclusive [55–57]. The most common AEs are dizziness
and drowsiness [17].
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Lamotrigine
Lamotrigine blocks voltage-sensitive Na+ channels, leading to the inhibition of neuronal
glutamate release. Glutamate is essential for the propagation of CSD, which many believe to be
the basis of the migraine aura [58]. Lamotrigine has been studied as part of a combination
therapy for headache prevention in one relatively large, prospective, open-label trial of 65
patients, most of whom had chronic migraine [59]. There were 17 (48.6%) responders, at a mean
dose of 55 mg/day. Those who had migraine with aura had a better response rate [12/18 (67%)],
including four of eight whose headaches were chronic. Another open-label study assessed the
impact of lamotrigine on aura itself and found that the drug significantly reduced both the
frequency and duration of aura [59].
Lamotrigine was not effective in a double-blind, randomized, parallel-groups trial [60]. This trial
was flawed because lamotrigine treatment was started at the full dose of 200 mg/day but,
following a high incidence of skin rashes, a slow dose-escalation was introduced. Whereas
studies indicate that lamotrigine is effective at preventing migraine with aura [61], it is unclear
whether it is effective in the absence of aura.
Other drugs
The neurotoxin botulinum toxin type A (BTN-A) inhibits the release of the neurotransmitter
acetylcholine at the neuromuscular junction, thereby inhibiting striated muscle contractions.
However, pain reduction often occurs before the decrease in muscle contractions, indicating an
alternative mechanism of action. The antinociceptive effect of BTN-A might be due to the ability
of the toxin to block substance P release, as demonstrated using an in vitro culture system. BTNA blocks the local release of glutamate and substance P in an in vivo model. Furthermore, the
production of FOS, a product of the immediate early gene cfos, expressed with neuronal stimuli
was prevented upon peripheral exposure to the toxin. These findings indicate that BTN-A blocks
peripheral sensitization and indirectly reduces central sensitization. The recent hypothesis that
migraine involves both peripheral and central sensitization could help to explain how BTN-A
inhibits migraine pain by acting on these two pathways. Oshinsky has shown that injecting BTNA into the forehead of rodents prevents the central sensitization of wide-dynamic-range neurons
in the TNC induced by applying an ‘inflammatory soup’ to the dura [62].
Pericranial BTN-A is effective as a prophylactic treatment of chronic moderate-to-severe
migraine [63]. In one trial (0, 25, or 75 U of BTN-A injected symmetrically into glabellar,
frontalis and temporalis muscles), the 25-U BTN-A treatment group fared significantly better
than did the placebo group, but the 75-U group did not. BTNA treatment was well tolerated but
high-dose BTN-A produced significantly more treatment-related AEs than did placebo. Recent
studies indicate that BTN-A is no more effective than placebo at preventing infrequent migraine
but is effective at preventing very frequent migraine [64].
Single controlled studies have supported the effectiveness of angiotensin-converting enzyme
(ACE) inhibitors, angiotensin receptor antagonists, riboflavin, coenzyme Q10 (CoQ10) and
butterroot at preventing episodic migraine. The evidence of effectiveness is better for NSAIDS
and conflicted for feverfew [65].
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Concluding remarks: setting treatment priorities
The goals of migraine preventive treatment are to reduce the frequency, duration or severity of
attacks, improve responsiveness to acute attack treatment, improve function and reduce
disability. It might also prevent the progression of episodic migraine to chronic migraine and
result in reductions in the cost of health care. The preventive medications with the bestdocumented efficacy are the β-blockers, amitriptyline, divalproex and topiramate. Choice of
medication is made based on the proven efficacy of a drug, the physician’s informed belief about
medications not yet evaluated in controlled trials, the AEs of a drug, patient preferences and
headache profile, and the presence or absence of coexisting disorders [66].
Coexistent diseases have important implications for treatment. In some instances, two or more
conditions can be treated with a single drug. However, this might be the exception rather than the
rule. In an effort to use a single medication to treat two conditions, one might select a second-or
third-tier choice for either or both conditions, which might not provide adequate treatment for
either. Managing two separate illnesses often requires different timelines for assessing drug
efficacy. It can take four or six weeks before improvement in migraine attack frequency or
severity is measurable. However, hypertension responds to the initiation of, or a change in,
treatment within one to two weeks. If individuals have more than one disease, certain categories
of treatment might be contraindicated. Although monotherapy is preferred, it is sometimes
necessary to combine preventive medications. Patients might require treatment with a
‘therapeutic independence’ approach, wherein each condition is treated separately. This requires
one to assess which medication is best suited for each illness independently, and might need
multiple physicians or specialists working together to provide optimal treatment
recommendations. Controlled trials are needed to determine the true advantage of this
combination treatment in episodic and chronic migraine.
New drugs for the preventive treatment of migraine are being developed based in part on an
increased understanding of migraine mechanisms. Despite the existence of guidelines for
migraine prevention, most patients are not receiving appropriate treatment. With increased
awareness and the continued development of new treatment, I believe that more patients will
receive appropriate care.
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